Short Interest in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Decreases By 26.3%

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) saw a large decrease in short interest in January. As of January 30th, there was short interest totaling 225,376 shares, a decrease of 26.3% from the January 15th total of 305,750 shares. Based on an average daily volume of 204,964 shares, the short-interest ratio is presently 1.1 days. Currently, 9.2% of the company’s stock are short sold. Currently, 9.2% of the company’s stock are short sold. Based on an average daily volume of 204,964 shares, the short-interest ratio is presently 1.1 days.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Ekso Bionics in a report on Monday, December 22nd. Wall Street Zen raised shares of Ekso Bionics to a “hold” rating in a report on Saturday, December 13th. Finally, HC Wainwright downgraded shares of Ekso Bionics from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 31st. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $10.50.

Ekso Bionics Price Performance

Ekso Bionics stock opened at $9.87 on Friday. The company has a market capitalization of $25.86 million, a price-to-earnings ratio of -1.74 and a beta of 0.80. The stock’s 50 day moving average is $7.62 and its 200-day moving average is $5.47. The company has a current ratio of 1.66, a quick ratio of 1.09 and a debt-to-equity ratio of 0.11. Ekso Bionics has a 12 month low of $2.73 and a 12 month high of $12.70.

Institutional Investors Weigh In On Ekso Bionics

A number of large investors have recently bought and sold shares of EKSO. Virtu Financial LLC acquired a new position in shares of Ekso Bionics in the third quarter valued at approximately $57,000. Shay Capital LLC bought a new stake in shares of Ekso Bionics in the third quarter worth $67,000. Citadel Advisors LLC acquired a new stake in Ekso Bionics in the third quarter valued at $198,000. Geode Capital Management LLC lifted its holdings in Ekso Bionics by 68.9% during the 4th quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock worth $218,000 after buying an additional 10,281 shares during the period. Finally, Consolidated Portfolio Review Corp bought a new stake in shares of Ekso Bionics in the 3rd quarter valued at about $333,000. 6.42% of the stock is currently owned by institutional investors and hedge funds.

About Ekso Bionics

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.